

The Global Immuno-Oncology Therapy Market: Present and Future (2015-2020)

<https://marketpublishers.com/r/G1EB4959A24EN.html>

Date: August 2016

Pages: 60

Price: US\$ 5,000.00 (Single User License)

ID: G1EB4959A24EN

Abstracts

RCubes Research and Consulting conducts deep dive market research on emerging technologies in the healthcare and life sciences industry.

The Global Immuno-Oncology Therapy Market: Present and Future (2015-2020), covers the oncology therapy market landscape, the prevalence of the main cancer types, the cost of treatment of key approved drugs, and the regulatory pathway. The report also provides information on the various drugs in different stages of development, profiles of companies that are on track to emerge as dominant players in this market. The report also provides expert commentary on the future of the market, on the strategies that will be successful in maintaining a leading position in this market.

RCubes estimates the oncology therapy market will be \$150 Billion by 2020 mainly driven by the legacy brands Rituxan & Avastin and by the immuno-oncology brands Revelimid, Opdivo, Keytruda, Xtandi etc.

Key Findings

Combination drugs prove to be more efficient and Companies will strive to develop/partner drugs which can form an effective combination with their existing/upcoming drugs.

Roche will emerge as a dominant player due to its strong legacy brands, impressive immuno-oncology portfolio and strong pipeline combined with its expertise in biotechnology.

BMS and Merck will compete with Opdivo and Keytruda respectively for

approvals as first line treatment for multiple indications.

Partnerships/Alliances will be rampant as pharmaceutical companies look out for opportunities in Immuno-Oncology that biotech companies will present.

Reasons to buy

The report will enable you to

Understand the Oncology therapy market - the emergence of Immuno-Oncology and its success in controlling disease progression & patient survival rates.

Develop a business strategy by understanding the prevalence of different types of cancers, the standard of care and the unmet need.

Develop a pricing and market access strategy by understanding the cost of treatment for drugs that are launched recently, the challenges posed by reimbursement watch dogs, and to understand what companies are doing to obtain a favorable pricing.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify and research opportunities in markets where there are unmet needs to fuel future growth.

Establish and maintain competitive information that delivers actionable insights to drive growth to core products and influence key product and marketing decisions.

Formulate business strategy by identifying growth pockets in the Oncology market and develop in-licensing/out-licensing and partnerships/acquisitions with established/emerging companies in this space.

Organize your R&D efforts by analyzing your competitor's development plan, current market presence.

Organize your sales and marketing efforts by identifying the market categories

and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Contents

- Introduction
- The Disease Burden
- Immunotherapy also Immuno oncology
- Monoclonal antibodies OR Mabs
- Adoptive cell transfer (ACT)
- Cytokines
- Therapeutic Cancer Vaccines
- Immunotherapy Landscape
- Emerging Immunotherapy
- CAR T
- Cost of Immuno oncology
- Regulation
- Astra Zeneca Oncology Pipeline
- Bristol Meyers Squibb Oncology Pipeline
- Competitive Landscape
- Novartis
- Pfizer
- Company Profiles
- Bristol Myer Squib
- Merck & Co
- Astra Zeneca
- Roche
- The Three C's of the Oncology Market
- Research Methodology
- Secondary Research
- Primary Research
- Models -48
- Forecasts
- Rcubes Market Research & Consulting
- About Us
- Contact Us
- Disclaimer -49

List Of Tables

LIST OF TABLES

- Table 1: Global Prevalence of Cancer, 2012 (In 000s)
- Table 2: Leading causes of death in US, 2014
- Table 3: Common Causes of Cancer Death, 2012
- Table 4: Estimated New Cancer Cases and Deaths in US, By Cancer Type, 2016
- Table 5: Cancer Survival Rates
- Table 6: Global Market for Oncology Therapy Market (2015)
- Table 7: The Future Product Lines Of Oncology Companies
- Table 8: Global Oncology Market, By Region
- Table 9: Top Oncology Drugs and Their Indications
- Table 10: Global Top 10 Selling Oncology Drugs in 2013 & 2015
- Table 11: Company Overview
- Table 12: Key Brands and Revenues
- Table 13: Geographical Split
- Table 14: Key Oncology Brands (\$M)
- Table 15: Company Overview -34
- Table 16: Key Brands and Revenues
- Table 17: Geography Split
- Table 18: Oncology Brands
- Table 19: Company Overview
- Table 20: Geographical Split
- Table 21: Oncology Brands
- Table 22: Company Overview
- Table 23: Key Brands and Revenues, 2015
- Table 24: Geographical Split (2015) -39
- Table 25: Oncology Brands (2014-16)
- Table 26: Top Oncology Companies (2014-2020)
- Table 27: Top Oncology Drugs By Revenues in 2020

List Of Figures

LIST OF FIGURES

- Figure 1: Cancer Survival Rates
- Figure 2: Immunotherapy
- Figure 3: Global Oncology Therapy Market, 2015
- Figure 4: Future of Oncology – Combination Therapies
- Figure 5: Astra Zeneca Oncology Pipeline
- Figure 6: Bristol Meyers Squibb Oncology Pipeline
- Figure 7: Roche Oncology Pipeline
- Figure 8: Top Ten Oncology Companies
- Figure 9: Top 15 Oncology Drugs, 2020

I would like to order

Product name: The Global Immuno-Oncology Therapy Market: Present and Future (2015-2020)

Product link: <https://marketpublishers.com/r/G1EB4959A24EN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1EB4959A24EN.html>